Make Informed Investment Decisions with Affordable Access to Experts
A Third View: Discussing the Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL) landscape and new drug developmentsTicker(s): RHHBY, NVS, TKPYY, MPSYF, MOR.F
Name: Dr Fredrick Hagemeister - MD
Institution: UT MD Anderson
- Internist and Professor of Medicine, Department of Lymphoma/Myeloma at MD Anderson Cancer Center.
- Sees about 2-3 new patients a week with relapsed/refractory DLBCL and regularly give lectures on the topic.
- Main interest has been on the management of Hodgkin and aggressive lymphomas; has participated in multiple clinical trials of management of patients with all types of lymphomas and has served as PI.
Please describe your background and clinical practice. Roughly how many patients with RR LDBCL do you currently manage?Added By: c_admin
How has the treatment paradigms in r/r/ DLBCL changed with respect to CAR-T therapies given the addition of new products.Added By: c_admin
What are your initial thoughts of the data available from MorphoSys' Phase 2 trial assessing the safety and efficacy of lenalidomide combined with MOR208?Added By: c_admin
Do you think the addition of Polatuzumab Vedotin (pola) to Bendamustine and Rituximab (BR) is an effective combination in treating r/r DLBCL?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.